URIST MARSHALL (EVP & Co-Head Research & Inv.) sold 50.0% of their position (20K shares) of ROYALTY PHARMA PLC on the open market
Open‑market sale worth $805.1K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/26/2026ACC: 0001838139-26-000008
Officer· EVP & Co-Head Research & Inv.
Since Dec 2020
-20K
Net shares
Net seller
$805.1K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
20K disposed
Non-Derivative Transactions1
Class A Ordinary Shares
Indirect
Shares
−20K
Price / share
$40.26
Trade value
$805.11K
% of position
50.0%
1/23/2026
40K→20K
Total
Net shares
−20K
Net value
-$805.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares Indirect | 1/23/2026 | S · Sale | −20K | $40.26 | $805.11K | 50.0% | 40K | 20K |
| Total | −20K | -$805.11K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Class A Ordinary Shares
DirectShares owned7.40K
Class A Ordinary Shares
IndirectShares owned19.02K
Total
7.40K direct·19.02K indirect26.42K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Ordinary Shares | 7.40K | Direct |
| Class A Ordinary Shares | 19.02K | Indirect |
| Total | 26.42K | 7.40K direct·19.02K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported